Unplanned Hospital Admissions in Patients With Solid Tumors in Brazil: Causes and Progressive Disease's Impact on Outcomes

• Published in: JCO global oncology 2024-07, Vol.10 (10), p.e2400063
• Main Authors: Hidalgo Filho, Cassio Murilo, Lazar Neto, Felippe, Sobottka, Vitor Pinheiro, da Rocha, João Wilson, Stangler, Lucas Tadeu Barrak, Andrade, Heloisa Guedes, Benfatti Olivato, Gustavo, Claro, Mateus Zapparoli, Souza, Danillo Zeferino de Oliveira, Yamamoto, Victor Junji, Soares, Mateus Marinho Nogueira, Estevez-Diz, Maria Del Pilar, Hoff, Paulo M, Bonadio, Renata Colombo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Brazil - epidemiology; Disease Progression; Female; Hospital Mortality; Hospitalization - statistics & numerical data; Humans; Male; Middle Aged; Neoplasms - epidemiology; Neoplasms - mortality; Neoplasms - therapy; Patient Readmission - statistics & numerical data; Retrospective Studies
• ISSN: 2687-8941; 2687-8941
• DOI: 10.1200/GO.24.00063

Most patients with cancer will be hospitalized throughout the disease course. However, most evidence on the causes and outcomes of these hospitalizations comes from administrative data or small retrospective studies from high-income countries. This study is a retrospective cohort of patients with solid tumors hospitalized from February 1, 2021, to December 31, 2021, in a tertiary cancer center in São Paulo, Brazil. We collected data on cancer diagnosis, symptoms at admission, hospitalization diagnosis, and survival clinical outcomes during in-hospital stay (in-hospital mortality) and after discharge (readmission rates and overall survival [OS]). Progressive disease (PD) diagnosis during admission was retrieved from manual chart review if explicitly stated by the attending physician. We modeled in-hospital mortality and postdischarge OS with logistic regression and Cox proportional hazards models, respectively. A total of 3,726 unique unplanned admissions were identified. The most common symptoms at admission were pain (40.6%), nausea (16.8%), and dyspnea (16.1%). PD (34.0%), infection (31.1%), and cancer pain (13.4%) were the most frequent reasons for admission. The in-hospital mortality rate was 18.9%. Patients with PD had a high in-hospital mortality rate across all tumor groups and higher odds of in-hospital death (odds ratio, 3.5 [95% CI, 3.0 to 4.2]). The 7-, 30-, and 90-day readmission rates were 11.9%, 33.5%, and 54%, respectively. The postdischarge median OS (mOS) was 12.6 months (95% CI, 11.6 to 13.7). Poorer postdischarge survival was observed among patients with PD (mOS, 5 months 18 months; < .001; hazard ratio, 2.4 [95% CI, 2.1 to 2.6]). PD is a common diagnosis during unplanned hospitalizations and is associated with higher in-hospital mortality rates and poorer OS after discharge. Oncologists should be aware of the prognostic implications of PD during admission and align goals of care with their patients.